What are the differences between herpes simplex virus type 1 (HSV‑1) and type 2 (HSV‑2) regarding transmission, typical lesions, recurrence rates, diagnosis, and management?

HSV-1 vs HSV-2: Key Clinical Differences

HSV-2 causes significantly more frequent genital recurrences and higher rates of asymptomatic viral shedding than HSV-1, making it the more transmissible and clinically problematic genital pathogen, while HSV-1 is increasingly responsible for first-episode genital herpes but recurs less often. 1

Epidemiology and Transmission

Prevalence Patterns

• HSV-1 seroprevalence in the US population aged 14-49 years is 47.8%, reflecting both oral and genital infections 2
• HSV-2 seroprevalence is 12.1% in the same population, nearly exclusively representing genital disease 2
• HSV-1 is now more common than HSV-2 as a cause of first-episode genital herpes in young women, with acquisition rates of 2.5 per 100 person-years for HSV-1 versus 1.1 per 100 person-years for HSV-2 3

Transmission Characteristics

• Asymptomatic viral shedding occurs more frequently with genital HSV-2 than HSV-1, particularly in the first 12 months after infection 1
• Sexual transmission can occur during asymptomatic periods for both types, but HSV-2 poses greater transmission risk 1
• Most HSV infections (74% of HSV-1 and 63% of HSV-2) occur without recognized signs or symptoms 3

Anatomic Site Preferences

Typical Lesion Locations

• HSV-1 primarily causes oral infection but is an increasing cause of genital herpes, particularly in well-resourced settings 2
• HSV-2 nearly exclusively causes genital disease 2
• Among men with recurrent genital herpes, rectal/perirectal lesions are more likely caused by HSV-1 (13.2%) than penile lesions 4

Clinical Presentation

• No significant differences exist in the clinical manifestations of genital HSV-1 versus genital HSV-2 disease during acute episodes 3
• Both types cause recurrent, self-limited genital ulcers 2, 5

Recurrence Rates

Frequency of Recurrences

• Most patients with first-episode genital HSV-2 infection will have recurrent episodes of genital lesions 1
• Genital HSV-1 recurs far less frequently than genital HSV-2 4
• HSV-1 is most prevalent among individuals with 0-2 recurrences in the previous year (9.1% of recurrent cases), indicating its lower recurrence tendency 4

Duration of Lesions

• Lesion duration is not significantly associated with virus type (hazard ratio 0.95% CI 0.65-1.38) 4
• Duration depends on sex (longer in males) and HIV status (longer in HIV-positive patients) rather than HSV type 4

Diagnosis

Active Lesions Present

• First-line: Nucleic acid amplification test (NAAT/PCR) with type differentiation (sensitivity and specificity >90%) 6
• Second-line: Viral culture if NAAT unavailable (acceptable but less sensitive) 6
• Do not use serologic testing when active genital ulcers are present—direct viral detection is required 6
• Avoid direct immunofluorescence or Tzanck smear due to insufficient sensitivity 6

No Active Lesions (Past Infection)

• Use type-specific IgG assays targeting glycoprotein G-1 (HSV-1) and G-2 (HSV-2) 6
• HSV-1 IgG assays have limited sensitivity (often <85%), missing 15-30% of true infections 6
• HSV-2 IgG assays (Roche and Bio-Rad) demonstrate high accuracy with sensitivity >97% and specificity >98% 6
• Low-positive results (index <3.0) require confirmation with Western blot or inhibition assay due to false-positive rates 6
• IgG antibodies may not become detectable until weeks to months after initial infection 6

Management

First Clinical Episode

• Acyclovir 400 mg orally 5 times daily for 7-10 days, OR 1
• Famciclovir 250 mg orally 3 times daily for 7-10 days, OR 1
• Valacyclovir 1 g orally twice daily for 7-10 days 1
• Treatment may be extended if healing is incomplete after 10 days 1

Recurrent Episodes (Episodic Therapy)

• Acyclovir 400 mg orally 3 times daily for 5 days, OR 1
• Acyclovir 800 mg orally twice daily for 5 days, OR 1
• Famciclovir 125 mg orally twice daily for 5 days, OR 1
• Valacyclovir 500 mg orally twice daily for 5 days 1
• Treatment should be initiated at first sign of prodrome or lesions 1

Suppressive Therapy

• Indicated for patients with ≥6 recurrences per year 1
• Acyclovir 400 mg orally twice daily, OR 1
• Famciclovir 250 mg orally twice daily, OR 1
• Valacyclovir 250-500 mg orally twice daily 1
• Reduces recurrence frequency by ≥75% 1
• Safety documented for acyclovir up to 6 years of continuous use 1
• Reassess need after 1 year as recurrence frequency decreases over time 1

Critical Counseling Points

Natural History

• Emphasize potential for recurrent episodes, asymptomatic viral shedding, and sexual transmission 1
• Patients with genital HSV-2 shed virus asymptomatically more frequently than those with HSV-1 1
• Frequency of recurrences decreases over time for many patients 1

Transmission Prevention

• Abstain from sexual activity when lesions or prodromal symptoms are present 1
• Use condoms during all sexual exposures with new or uninfected partners 1
• Inform sex partners about genital herpes diagnosis 1
• Suppressive therapy reduces but does not eliminate asymptomatic shedding 1

Pregnancy Considerations

• Explain neonatal infection risk to all patients, including men 1
• Childbearing-aged women must inform prenatal care providers about HSV infection 1

Common Pitfalls

• Do not rely on HSV-1 serology to exclude infection—negative results cannot rule out prior HSV-1 due to poor sensitivity 6
• Verify which commercial platform your laboratory uses for HSV-2 testing—DiaSorin has substantial false-positive rates (31% at 12% prevalence) compared to Roche/Bio-Rad 6
• Do not assume genital HSV-1 will recur as frequently as HSV-2—this distinction affects counseling about suppressive therapy needs 4
• Recognize that most HSV transmission occurs from persons unaware of their infection or during asymptomatic periods 1, 7